Patrick Saulnier
Overview
Explore the profile of Patrick Saulnier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
4593
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daoud L, Hoang S, Milin-Moguerou A, Eyer J, Breton T, Montembault V, et al.
Biomacromolecules
. 2025 Feb;
26(3):1923-1934.
PMID: 40008451
The biological application of gold nanospheres (AuNSs) is often constrained by their stability and cytotoxicity. We present a greener synthetic approach that gives a simple and more environmentally friendly route...
2.
Lebreton V, Legeay S, Rapenne C, Saulnier P, Lagarce F
Nanomedicine (Lond)
. 2024 May;
19(13):1123-1131.
PMID: 38690778
The present study investigated renal elimination after intravenous administration of four different formulations of lipid nanocapsules (LNCs) containing dyes adapted to Förster resonance energy transfer (FRET-LNCs). FRET-LNCs of 85 or...
3.
Roger E, Franconi F, Do T, Simonsson C, Siegler B, Perrot R, et al.
J Control Release
. 2023 Nov;
364:700-717.
PMID: 37951474
Nanoemulsions are metastable emulsions in the nanometric range which can be obtained using low-energy processes. A decade ago, it was demonstrated that a non-negligible amount of residual surfactant micelles may...
4.
Naigeon M, Roulleaux Dugage M, Danlos F, Boselli L, Jouniaux J, de Oliveira C, et al.
Sci Adv
. 2023 Nov;
9(45):eadh0708.
PMID: 37939189
Circulating senescent CD8 T (Tsen) cells are characterized by a lack of proliferative capacities but retain cytotoxic activity and have been associated to resistance to immunotherapy in patients with advanced...
5.
Lebreton V, Legeay S, Vasylaki A, Lagarce F, Saulnier P
Eur J Pharm Sci
. 2023 Jul;
189:106537.
PMID: 37490974
The parameters currently used for characterization of nanoparticles, such as size and zeta potential, were not able to reflect the performance of a nanocarrier in the biological environment. Therefore, more...
6.
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al.
Nat Med
. 2023 Jul;
29(8):2110-2120.
PMID: 37488289
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd...
7.
Gazaille C, Bozzato E, Madadian-Bozorg N, Mellinger A, Sicot M, Farooq U, et al.
Biomater Adv
. 2023 Jul;
153:213549.
PMID: 37453243
The objective of this work was to develop an implantable therapeutic hydrogel that will ensure continuity in treatment between surgery and radiochemotherapy for patients with glioblastoma (GBM). A hydrogel of...
8.
Bigot P, Bernhard J, Khene Z, Dariane C, Lebdai S, Doumerc N, et al.
BJU Int
. 2023 Jul;
132(5):575-580.
PMID: 37433580
Objective: To evaluate prospectively the effects of surgical excision of renal tumours on blood pressure (BP). Patients And Methods: In a multicentre prospective study, we evaluated 200 patients who underwent...
9.
Doualle C, Gouju J, Nouari Y, Wery M, Guittonneau C, Codron P, et al.
Am J Cancer Res
. 2023 May;
13(4):1425-1442.
PMID: 37168329
Glioblastoma is an aggressive brain tumor with a poor prognosis. Glioblastoma Stem Cells (GSC) are involved in glioblastoma resistance and relapse. Effective glioblastoma treatment must include GSC targeting strategy. Robust...
10.
Courtillie E, Fromage B, Augusto J, Saulnier P, Subra J, Bonnaud-Antignac A
J Nephrol
. 2023 Jan;
36(3):841-849.
PMID: 36670295
Background: Kidney transplantation is the treatment of choice for end-stage renal disease. Psychological problems and the presence of high anxiety have been described at various times over the course of...